PARIS Alexander M.M. Eggermont, MD, PhD, director of the Cancer Institute Gustave Roussy in Villejuif, France, highlights the high response rates that have been associated with BRAF inhibitors such as vemurafenib or dabrafenib, yet notes that their impact on survival is limited due to short duration. In addition, chemotherapy in combination with ipilimumab has significantly not improved results. According to Eggermont, while the combination of dabrafenib and trametenib have been found to significantly improve response rates and PFS and OS rates among BRAF-mutated patients, the phase III verdict on the superiority of this combination remains to be established.
Videos that have been watched and reviewed by peers and found to meet the standards of this site are labeled "Magnified."
Anyone can upload or link to a video for this channel. From here, videos are reviewed by site peers, and videos that meet site standards are labeled "Magnified" and become searchable and visible for all site visitors.